

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  VON DER KAMMER <i>et al.</i>  Appl. No.: <i>To be assigned</i> (U.S. Nat'l Phase of PCT/EP2004/052684)  I.A. Filing Date: October 28, 2004  For: <b>Diagnostic and Therapeutic Use of the Human DAX-1 Gene and Protein for Neurodegenerative Diseases</b>	Confirmation No.: <i>To be assigned</i>  Art Unit: <i>To be assigned</i>  Examiner: <i>To be assigned</i>  Atty. Docket: 2335.0160000/SRL/KPQ
---	---

**Authorization to Treat a Reply as Incorporating an  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Katrina Y. Pei Quach  
Agent for Applicants  
Registration No. 51,063

Date: May 1, 2006

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600